Congenital Hyperinsulinism Market Expected to Experience Major Growth by 2034, According to DelveInsight | Zealand Pharma, Rezolute, Eiger BioPharma, Crinetics, AmideBio, Hanmi pharmaceutical

Posted on
by

Congenital Hyperinsulinism Market Expected to Experience Major Growth by 2034, According to DelveInsight | Zealand Pharma, Rezolute, Eiger BioPharma, Crinetics, AmideBio, Hanmi pharmaceutical
The Key Congenital Hyperinsulinism Companies in the market include – Zealand Pharma, Rezolute, Eiger BioPharmaceuticals, Crinetics, AmideBio, Hanmi pharmaceutical, and others.

 

DelveInsight’s “Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Congenital Hyperinsulinism, historical and forecasted epidemiology as well as the Congenital Hyperinsulinism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Congenital Hyperinsulinism market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Congenital Hyperinsulinism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congenital Hyperinsulinism Market Insights

 

Some of the key facts of the Congenital Hyperinsulinism Market Report:

  • The Congenital Hyperinsulinism market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In January 2025, Rezolute, an affiliate of Handok, announced that the FDA has granted Breakthrough Therapy Designation to RZ358 (ersodetug) for treating hypoglycemia associated with congenital hyperinsulinism.

  • In December 2024, Sidra Medicine, a member of Qatar Foundation, has conducted the industry-sponsored ‘sunRIZE’ trial focused on pediatric congenital hyperinsulinism. This marks the first pharmaceutical trial following the launch of Sidra’s ‘Clinical Trials Program,’ which aims to enhance treatment options for rare and complex diseases in the Arab region. The Phase III sunRIZE trial is being led by biopharmaceutical company Rezolute.

  • In October 2024, Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company specializing in peptide-based medicines, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of its New Drug Application (NDA) for dasiglucagon. The application sought approval for dasiglucagon to prevent and treat hypoglycemia in pediatric patients aged seven days and older with congenital hyperinsulinism (CHI) for up to three weeks of dosing.

  • DelveInsight’s estimates indicate that in 2023, the diagnosed prevalent cases of Congenital HyperInsulinism in the United States accounted for around 20% of the total cases across the 7MM.

  • According to DelveInsight’s consultant estimates, the diffuse type accounted for the majority of Congenital HyperInsulinism (CHI) cases, comprising approximately 75% of CHI cases in the United States in 2023.

  • Mutation-specific prevalence analysis indicates that ABCC8 and KCNJ11 mutations are more frequently observed in CHI patients compared to other mutations.

  • Zealand Pharma plans to resubmit its New Drug Application (NDA) to the FDA in early 2024 for ZEGALOGUE (dasiglucagon), which is being evaluated for treating pediatric hypoglycemia in congenital hyperinsulinism (CHI) patients. This follows a 2023 Complete Response Letter addressing concerns related to the manufacturing facility.

  • Key Congenital Hyperinsulinism Companies: Zealand Pharma, Rezolute, Eiger BioPharmaceuticals, Crinetics, AmideBio, Hanmi pharmaceutical, and others

  • Key Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others

  • The Congenital Hyperinsulinism epidemiology based on mutation specific cases analyzed that mutation in ABCC8 and KCNJ11 genes are more common than other mutations of Congenital Hyperinsulinism in the 7MM

 

Congenital Hyperinsulinism Overview

Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.

 

Get a Free sample for the Congenital Hyperinsulinism Market Report:

https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market

 

Congenital Hyperinsulinism Market

The dynamics of the Congenital Hyperinsulinism market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2020-2034.

“Congenital Hyperinsulinism (CHI) pipeline is not robust, however it possess promising and potential drugs in clinical stage of developments, which are expected to be launched in the near future. Dasiglucagon is currently in the Phase III stage of development followed by RZ358 and Avexitide that are in Phase II clinical development stage. Out of these therapies, RZ358 has already completed a Phase II clinical developmental trial.”

 

Congenital Hyperinsulinism Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Congenital Hyperinsulinism Epidemiology Segmentation:

The Congenital Hyperinsulinism market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Congenital Hyperinsulinism

  • Prevalent Cases of Congenital Hyperinsulinism by severity

  • Gender-specific Prevalence of Congenital Hyperinsulinism

  • Diagnosed Cases of Episodic and Chronic Congenital Hyperinsulinism

 

Download the report to understand which factors are driving Congenital Hyperinsulinism epidemiology trends @ Congenital Hyperinsulinism Epidemiological Insights

 

Congenital Hyperinsulinism Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Hyperinsulinism market or expected to get launched during the study period. The analysis covers Congenital Hyperinsulinism market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congenital Hyperinsulinism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Congenital Hyperinsulinism Therapies and Key Companies

  • Dasiglucagon: Zealand Pharma

  • RZ358: Rezolute

  • Avexitide: Eiger BioPharmaceuticals

  • CRN04777: Crinetics

  • ABG-023: AmideBio

  • HM15136: Hanmi pharmaceutical

 

To know more about Congenital Hyperinsulinism treatment, visit @ Congenital Hyperinsulinism Medications

 

Congenital Hyperinsulinism Market Drivers

  • The Congenital Hyperinsulinism emerging pipeline holds the pioneering therapies in competition due to the presence of only one approved therapy, which provides an upper hand for initiating research and development in this area

  • One of the major strengths of this market is the increasing research, awareness and support for the disease will drive the market in the long run

 

Congenital Hyperinsulinism Market Barriers

  • The major weakness of the market is the fact that Congenital Hyperinsulinism can relapse in some cases

  • There is a significant lack of proper diagnosis and management of Congenital Hyperinsulinism, which clearly depicts that the management and diagnosis paradigm of Congenital Hyperinsulinism is to date under studied and needs to be updated

 

Scope of the Congenital Hyperinsulinism Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Congenital Hyperinsulinism Companies: Zealand Pharma, Rezolute, Eiger BioPharmaceuticals, Crinetics, AmideBio, Hanmi pharmaceutical

  • Key Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others

  • Congenital Hyperinsulinism Therapeutic Assessment: Congenital Hyperinsulinism current marketed and Congenital Hyperinsulinism emerging therapies

  • Congenital Hyperinsulinism Market Dynamics: Congenital Hyperinsulinism market drivers and Congenital Hyperinsulinism market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Congenital Hyperinsulinism Unmet Needs, KOL’s views, Analyst’s views, Congenital Hyperinsulinism Market Access and Reimbursement

 

Discover more about therapies set to grab major Congenital Hyperinsulinism market share @ Congenital Hyperinsulinism Treatment Market

 

Table of Contents

1. Congenital Hyperinsulinism Market Report Introduction

2. Executive Summary for Congenital Hyperinsulinism

3. SWOT analysis of Congenital Hyperinsulinism

4. Congenital Hyperinsulinism Patient Share (%) Overview at a Glance

5. Congenital Hyperinsulinism Market Overview at a Glance

6. Congenital Hyperinsulinism Disease Background and Overview

7. Congenital Hyperinsulinism Epidemiology and Patient Population

8. Country-Specific Patient Population of Congenital Hyperinsulinism

9. Congenital Hyperinsulinism Current Treatment and Medical Practices

10. Congenital Hyperinsulinism Unmet Needs

11. Congenital Hyperinsulinism Emerging Therapies

12. Congenital Hyperinsulinism Market Outlook

13. Country-Wise Congenital Hyperinsulinism Market Analysis (2020–2034)

14. Congenital Hyperinsulinism Market Access and Reimbursement of Therapies

15. Congenital Hyperinsulinism Market Drivers

16. Congenital Hyperinsulinism Market Barriers

17. Congenital Hyperinsulinism Appendix

18. Congenital Hyperinsulinism Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/